文献速递血液透析通路

多病共存与动静脉瘘创建结局的关联

The association between multimorbidity and arteriovenous fistula creation outcomes.
PubMed 文献 · J Vasc Surg · 2026-01-29

本研究基于VQI与USRDS链接数据,回顾性分析2011至2019年9023例血液透析动静脉瘘(AVF)创建患者,以多病共存加权指数(MWI)评估疾病负担。结果显示MWI高于中位数者6个月内AVF使用率更低(58.9% vs 64.6%)、首次使用前修订率更高(43.2% vs 36.2%),且中位生存期更短(35 vs 50个月)。

要点

  • MWI高于中位数与6个月内AVF使用率降低独立相关。
  • MWI高于中位数者首次AVF使用前修订风险增加。
  • MWI高于中位数者中位生存期更短,提示预后更差。

核心结论

  • AVF创建患者MWI较高,高MWI与死亡率增加、6个月内AVF使用可能性降低及首次使用前修订 odds 增加相关。
  • MWI可能作为血管通路规划和共享决策的有价值辅助工具。

研究设计与样本

  • 共纳入9023例患者,平均年龄65岁,以男性和白人为主,中位随访14个月(IQR 3-33个月)。
  • 主要暴露为MWI,按中位数二分为高于或低于/等于中位数;主要结局为6个月内AVF功能使用。
  • 采用多变量逻辑回归,协变量包括年龄、性别、种族、穿刺部位和MWI。

主要发现

  • 9023例AVF中5578例(61.8%)在创建后6个月内使用,首次使用中位时间4个月(IQR 3-5个月)。
  • 上臂AVF较前臂更可能在6个月内使用(62.7% vs 59.4%;P = .004)。
  • 5578例6个月内使用AVF的患者中,2199例(39.4%)首次使用前需至少一次修订,其中多数接受一次(73.8%)或两次(21.3%)修订。
  • MWI高于中位数者较低于/等于中位数者6个月内AVF使用率更低(58.9% vs 64.6%;P < .001),首次使用前修订率更高(43.2% vs 36.2%;P < .001)。
  • MWI高于中位数者中位生存期更短(35个月 vs 50个月;P < .001)。

关键数值与推荐

  • MWI中位数为8.3。
  • 6个月内AVF使用率:MWI高于中位数58.9%,低于/等于中位数64.6%(P < .001)。
  • 首次使用前修订率:MWI高于中位数43.2%,低于/等于中位数36.2%(P < .001)。
  • 中位生存期:MWI高于中位数35个月,低于/等于中位数50个月(P < .001)。

临床怎么用

  • 对于AVF创建患者,可考虑使用MWI评估多病共存负担以辅助血管通路规划。
  • 高MWI患者应预期6个月内AVF使用率较低且首次使用前修订风险较高,需加强随访和共享决策。
  • 高MWI患者生存期较短,通路规划时需综合评估预后。

局限性

  • 回顾性研究设计,可能存在未测量混杂。
  • MWI按中位数二分,可能损失连续变量信息。
  • 研究人群以男性和白人为主,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The multimorbidity weighted index (MWI) quantifies both cumulative disease burden and its impact on physical functioning. This study examined the association between MWI and short-term outcomes of arteriovenous fistula (AVF) creation for hemodialysis access. METHODS: We performed a retrospective review of AVFs created between January 2011 and December 2019 of national Vascular Quality Initiative data linked to United States Renal Data Systems data. The primary exposure was multimorbidity as measured by the MWI. The MWI was dichotomized as above or below the median. The primary outcome was functional AVF use within 6 months. Multivariable logistic regression was performed with age, sex, race, cannulation site, and MWI as covariates. RESULTS: A total of 9023 patients were included. The mean age was 65 years and the cohort was predominantly male and identified as White. The median follow-up was 14 months (interquartile range, 3-33 months). The median MWI was 8.3. Of the 9023 AVF created, 5578 (61.8%) were used within 6 months of creation, and the median time to first use was 4 months (interquartile range, 3-5 months). Upper arm AVFs were more likely to be used within 6 months than forearm (62.7% vs 59.4%; P = .004). Of the 5578 patients who used their access within 6 months, 2199 (39.4%) required at least one revision before first AVF use, with most undergoing one (73.8%) or two (21.3%) revisions. Patients with an MWI greater than the median (>MED) compared with patients with MWI less than or equal to the median (<MED) were less likely to use their AVF within 6 months (58.9% vs 64.6%; P < .001) and more likely to undergo revision before first AVF use (43.2% vs 36.2%; P < .001). The median survival was shorter for patients in >MED (35 months vs 50 months; P < .001). On multivariable analysis, MWI >MED, female sex, Black race, and age >80 years were associated with a decreased odds of AVF use within 6 months. An MWI >MED, female sex, Asian and Black race, and upper arm cannulation site were associated with an increased odds of undergoing a revision before first AVF use. CONCLUSIONS: Patients undergoing AVF creation have a high MWI. In this cohort, a higher MWI was associated with increased mortality, a lower likelihood of AVF use within 6 months, and greater odds of revision before first AVF use. The MWI may be a valuable adjunct to guide vascular access planning and shared decision-making.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lopez JL, Yuo TH, Siavoshi M, et al. The association between multimorbidity and arteriovenous fistula creation outcomes. J Vasc Surg. 2026. PMID: 41616877. doi:10.1016/j.jvs.2026.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。